Financial Lp Hrt Sells 10,580 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 10,580 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $3.33, for a total transaction of $35,231.40. Following the completion of the sale, the insider directly owned 70,805 shares of the company’s stock, valued at $235,780.65. The trade was a 13.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total transaction of $65,229.12.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total transaction of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt bought 7,851 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Down 8.1%

Shuttle Pharmaceuticals stock traded down $0.29 during mid-day trading on Thursday, reaching $3.28. 125,987 shares of the company’s stock were exchanged, compared to its average volume of 555,046. The business’s fifty day simple moving average is $5.30 and its 200 day simple moving average is $10.27. Shuttle Pharmaceuticals Holdings, Inc. has a one year low of $2.90 and a one year high of $55.90. The firm has a market capitalization of $2.10 million, a PE ratio of -0.07 and a beta of 0.29.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SHPH shares. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the fourth quarter worth $26,000. Boothbay Fund Management LLC purchased a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at $37,000. Ikarian Capital LLC purchased a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at $124,000. Finally, Connective Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at $357,000. 4.58% of the stock is owned by institutional investors.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .